Information Provided By:
Fly News Breaks for December 17, 2015
ROSG
Dec 17, 2015 | 19:33 EDT
Cantor analyst Bryan Brokmeier initiate coverage of Rosetta Genomics with a Speculative Buy rating and a $3-5 fair value on shares.
News For ROSG From the Last 2 Days
There are no results for your query ROSG